[Anesthetic management of a hemophilia A patient with HIV infection: a case report].
A 40-year-old male with hemophilia A was scheduled for right total knee arthroplasty. He was HIV positive probably due to receiving infected blood products previously. We performed the pharmacokinetic study of factor VIII in advance, which showed the increased factor VIII activity 1.6% by an injection of one unit. kg-1 of factor VIII and the half-life of about 16 hours. To keep the factor VIII activity over 100% in the perioperative period, 3000 units of recombinant factor VIII was injected one hour before the induction of anesthesia followed by continuous infusion at 125 units per hour. The factor VIII activity before the induction was 110.6%. The operation was successful and there was no sign of bleeding tendency. The factor VIII activity after the operation, however, was unexpectedly low (73.1%), and it was necessary to increase the infusion rate to 150 units per hour. The factor VIII activity was kept over 80% until POD 7 with the continuous infusion and over 60% until POD 21 with intermittent administration. Factor VIII was discontinued on POD 21 without any sign of bleeding tendency after the postoperative rehabilitation. Although this patient was HIV positive, his immune system was well controlled with HAART and there was no difficulty in the anesthetic management. To prevent accidental infection to the medical staff, we again recognized the importance of standard precautions.
Bougaki
Masahiko
M
Department of Anesthesiology, Faculty of Medicine, University of Tokyo, Tokyo 113-8655.
Tomioka
Toshiya
T
Hanaoka
Kazuo
K
D000328:Adult; D000768:Anesthesia, General / Q000379:methods*; D019645:Arthroplasty, Replacement, Knee; D005169:Factor VIII / Q000008:administration & dosage / Q000032:analysis; D015658:HIV Infections / Q000209:etiology*; D006467:Hemophilia A / Q000150:complications*; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage
D011994:Recombinant Proteins; C078147:F8 protein, human; D005169:Factor VIII